Wengang Zhang
107 Wenhuaxi Road
Jinan, China
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.
Journal: BMC pulmonary medicine
Published: May 08, 2023
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Journal: Frontiers in immunology
Published: August 29, 2022
ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Journal: BMC pulmonary medicine
Published: August 13, 2022
Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer.
Journal: Frontiers in pharmacology
Published: August 07, 2022
PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Journal: Frontiers in immunology
Published: July 11, 2022
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Journal: Frontiers in oncology
Published: June 25, 2022
Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Journal: Critical reviews in oncology/hematology
Published: April 12, 2022
CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.
Journal: Frontiers in oncology
Published: February 01, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026